硫酸沙丁胺醇(Salbutamol sulfate) - 药物靶点：β2-adrenergic receptor_在研适应症：运动诱发哮喘，支气管痉挛，气道阻塞_专利_临床

概要

基本信息

药物类型

小分子化药

别名

ALBUTEROL、ALBUTEROL SULFATE、Salbutamol

+ [53]

靶点

β2-adrenergic receptor

作用方式

激动剂

作用机制

β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

GlaxoSmithKline Intellectual Property Ltd.

GSK Plc

Kindeva Drug Delivery LP

+ [4]

非在研机构

Schering Corp.NORVIUM BIOSCIENCE

Boehringer Ingelheim GmbH

+ [2]

权益机构-

最高研发阶段批准上市

首次获批日期

日本 (1973-01-13),

气道阻塞哮喘支气管炎+ [2]

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C13H23NO7S

InChIKeyOVICLFZZVQVVFT-UHFFFAOYSA-N

CAS号51022-70-9

关联

448

项与硫酸沙丁胺醇相关的临床试验

NCT06980727

/ Not yet recruiting临床3期IIT

Increment Value of Intravenous Dexametasone Versus Nebulized Salbutamol for Renal Colic Pain Management in the Emergency Department: A Randomized Clinical Trial

Adult patients (18-55 years of age) with clinical diagnosis of acute renal colic (sudden sharp colic flank pain with or without radiation to genitalia or groin and with or without urinary symptoms) who had pain score of 5 or more measured by 10-cm visual analogue scale (VAS), will be included. Will be excluded those who had history of cardiovascular, hepatic, renal or metabolic diseases, patients with evidence of sepsis or clinical suspicion of urinary tract infection, hemodynamically unstable patients (systolic blood pressure <90 mmHg), patients with uncontrolled diabetes, pregnancy, breastfeeding, patients unable to understand verbal and/or written information, patients receiving analgesics within 6 hours before presentation, serum potassium less than 3.7 mmol/l, concomitant use of any beta blockers (including beta-blocker containing eye drops), prolonged-release long-acting β-agonists, use of short-acting β2-agonists within the 6 h preceding presentation to the emergency department, any contraindication to the use of salbutamol, history of drug dependence or chronic consumption of alcohol. Will be also excluded patients with known allergy to paracetamol or salbutamol, patients with abdominal tenderness as a sign of peritoneal inflammation and those with any clinical suspicion for diseases other than urolithiasis, including abdominal aortic aneurysm or dissection.

开始日期2025-06-01

申办/合作机构

Université de Monastir

CTRI/2025/04/085680

/ Not yet recruitingN/AIIT

Effect of nebulised budesonide and salbutamol versus ipratropium bromide and salbutamol in the management of acute exacerbation of wheeze moderate to severe in children aged 1 to 5 years A Randomized controlled trial - nil

开始日期2025-05-08

申办/合作机构-

CTIS2024-514065-19-00

/ Recruiting临床3期IIT

PHASE III, DOUBLE-BLIND, RANDOMIZED, CONTROLLED, NON-INFERIORITY, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY OF SALBUTAMOL MONOTHERAPY COMPARED TO SALBUTAMOL PLUS IPRATROPIUM BROMIDE IN THE MANAGEMENT OF MODERATE ACUTE ASTHMATIC EXARCEBATIONS IN CHILDREN IN THE EMERGENCY DEPARTMENT

开始日期2025-04-11

申办/合作机构-

100 项与硫酸沙丁胺醇相关的临床结果

登录后查看更多信息

100 项与硫酸沙丁胺醇相关的转化医学

登录后查看更多信息

100 项与硫酸沙丁胺醇相关的专利（医药）

登录后查看更多信息

16,929

项与硫酸沙丁胺醇相关的文献（医药）

2025-12-01·HISTOCHEMISTRY AND CELL BIOLOGY

The amelioration effects of ankaferd blood stopper, platelet gel, and Momordica charantia on peripheral nerve injury in the rats: a stereological and ultrastructural study

Article

作者: Geuna, Stefano ; Raimondo, Stefania ; Altun, Gamze ; Kaplan, Suleyman ; Önger, Mehmet Emin ; Deniz, Ömür Gülsüm ; Elhaj, Abubaker El

Peripheral nerve injuries are commonly encountered in clinical practice. Peripheral nerve injuries most commonly result in serious problems affecting quality of life. The present study is designed to research the possible neuroprotective effects of Ankaferd blood stopper (ABS), platelet-rich plasma (PRP), and Momordica charantia (MC) on regeneration using unbiased stereological techniques. In total, 30 female 8-10 week Sprague Dawley rats were randomly divided into five equal groups; control (CG), the group exposed to sciatic nerve resection (Gap) (CGG), additionally following the surgical process ABS, MC, and PRP were injected into collagen tube (ABSG, MCG, PRPG). Nucleator and fractionator methods were used to estimate the number of myelinated and unmyelinated axons, axon area, and myelin sheath thickness. Also, an electron microscopic evaluation was performed. Regarding the number of myelinated axons, significant increases were found in the ABSG, MCG, and PRPG compared with CG (p < 0.05). The protective effects of ABS, PRP, and MC on peripheral nerve regeneration in experimental models in rats were shown using electrophysiological and stereological assessment parameters.

2025-08-01·Journal of Environmental Sciences

Metal leaching accompanied with natural photo-aging behavior of e-waste plastic derived microplastics in aquatic environment

Article

作者: Liu, Lili ; Wang, Lijuan ; Qi, Ruimin ; Zhang, Jianshuai ; Tang, Yuanyuan ; Yu, Shuyuan ; Chi, Yihan ; Xu, Zhe

As the main component of electronic products, plastics contain complex and diverse metal additives. Recycling process is not conducive to stable existence of metal additives in electronic plastics. Once the e-waste plastics enter the environment, they will continue to release harmful metals into environment after aging, causing serious hazards. This study delved into the analysis and comparison of metal content of e-waste plastics, elucidating aging process and metal leaching behavior over a 112-day natural light exposure period. The findings underscored that metal content in recycled plastics surpassed that in their new counterparts. Specifically, Ti content in new plastics remained below 100 mg/kg, while recycled plastics exhibited Ti content surpassing 100 mg/kg threshold. Throughout prolonged natural light exposure, metals such as Zn, Ba and Sb demonstrated a heightened likelihood of release from electronic plastics in comparison to other metals. The aging process during light exposure led to fragmentation of electronic plastics, accompanied by a reduction in particle size. Notably, the particle size reduction was more pronounced in poly acrylonitrile butadiene styrene (ABS) and recycled ABS, experiencing reductions of 40 µm and 85 µm, respectively. This phenomenon was attributed to the presence of polybutadiene structural units, which proved more susceptible to aging. Along with the breaking of plastics, the ABS plastics released metal species such as Pb, Cd, Ni, Al that had not been detected in other plastics solutions. The collective evidence from this study suggested that ABS and recycled ABS electronic plastics might pose a heightened potential environmental risk compared to other electronic plastics.

2025-07-01·ENVIRONMENTAL RESEARCH

Asthma medication usage after environmental exposure to wildfire smoke: A systematic review

Review

作者: Etherington, Cathy ; Vardoulakis, Sotiris ; Nguyen, Van ; Thompson, Vanessa ; Lazarevic, Nina ; Rushby, Anne-Marie

Asthma is a chronic respiratory condition exacerbated by exposure to particulate air pollution. Smoke from landscape fires has been associated with increased mortality, asthma-related admissions to emergency and other hospital departments, and uptake in primary care services. With climate change and more frequent landscape fires, healthcare systems must prepare for disaster, including surges in asthma medication demand. Past reviews have not resolved the direction and magnitude of the association between PM_2.5 exposure during landscape fires and asthma medication use. The aim of this review was to investigate the relationship between exposure to landscape fire smoke and the use of asthma medications. We conducted a systematic review of PubMed, Scopus, and Web of Science, identifying peer-reviewed articles that examined asthma medication usage following environmental exposure to landscape fire smoke. After a full-text review, we identified twelve articles, three from Canada, three from the USA and six from Australia, with five being retrospective cohort studies. Despite differences in study design, outcome and exposure assessment, the included studies reported a consistent increase in asthma medication use after exposure to wildfires. There is consistent evidence that exposure to wildfire smoke is associated with an increase in the use of reliever medications, particularly salbutamol. Increases in other asthma management medications were also consistently identified. Increases in demand for asthma medications after exposure to wildfire smoke highlight the urgent need to address the growing frequency and intensity of wildfires driven by climate change.

310

项与硫酸沙丁胺醇相关的新闻（医药）

2025-05-21

·Firstwordpharma

AstraZeneca eyes wider age demographic for asthma rescue therapy Airsupra

Looking to introduce a new standard-of-care asthma rescue therapy across a broader age group, AstraZeneca unveiled detailed results from a Phase IIIb study of Airsupra (albuterol/budesonide) at the American Thoracic Society (ATS) annual meeting on Monday.The UK pharma had announced top-line results from the BATURA trial’s prespecified interim analysis in October last year, wherein Airsupra demonstrated a significant and clinically meaningful reduction in the risk of severe exacerbations versus albuterol alone in patients 12 and older with intermittent or mild persistent asthma on a short-acting beta2-agonist (SABA) alone, or as-needed SABA accompanied by either low-dose inhaled corticosteroid or leukotriene receptor antagonist maintenance therapy.Full results, also published in the NEJM, showed that AstraZeneca’s inhaled combination therapy met the study’s primary endpoint, cutting the risk of severe exacerbations by 47% compared with albuterol alone. This “unprecedented” efficacy outcome at a time point prompted an early termination of the trial as reported earlier.On a key secondary endpoint, patients receiving Airsupra experienced 63% lower exposure to systemic corticosteroids over the treatment period versus albuterol alone. Similar gains on all endpoints were seen in a subgroup of adult patients. Meanwhile, the safety profile of inhaled therapy remained consistent with previous studies, showing no clinically meaningful differences between treatment groups.“We hope these comprehensive results accelerate the use of anti-inflammatory rescue therapy as the preferred standard of care, in line with recommendations from the Global Initiative for Asthma,” remarked Sharon Barr, head of biopharmaceuticals R&D at AstraZeneca.Co-developed by AstraZeneca and Avillion, Airsupra secured FDA approval in 2023 as rescue medication for as-needed treatment of bronchoconstriction and exacerbation risk reduction in adults with asthma, but was turned down by the regulator for use in a younger population. Jefferies analysts predicted a peak sales of $1.8B for Airsupra after the results top-lined last year.

临床结果临床3期上市批准

2025-05-20

·求实药社

降低哮喘恶化风险近50%，阿斯利康“first-in-class”疗法公布3b期临床试验结果

来源：药明康德降低哮喘恶化风险近50%，阿斯利康“first-in-class”疗法登《新英格兰医学杂志》阿斯利康（AstraZeneca）今日宣布，3b期临床试验BATURA的完整结果显示，其“first-in-class”哮喘疗法Airsupra（沙丁胺醇/布地奈德），在所有主要和次要终点上均较沙丁胺醇组实现具有统计学显著性和临床意义的改善。该研究结果已发表于《新英格兰医学杂志》。该试验比较了按需使用Airsupra与按需使用沙丁胺醇在轻度哮喘患者中的疗效。试验结果显示，使用Airsupra治疗可将疾病严重恶化风险显著降低47%（HR=0.53；95% CI：0.39，0.73；p<0.001）。由于在预设中期分析中观察到Airsupra的显著疗效，独立数据监查委员会建议提前终止试验。在一项关键性次要终点中，12岁及以上的青少年和成人在使用Airsupra治疗期间，系统性糖皮质激素（SCS）暴露总量较沙丁胺醇组降低63%（p<0.001），从而减少了累积使用SCS带来的已知风险。Airsupra是一种“first-in-class”短效β2受体激动剂（SABA）和吸入型糖皮质激素（ICS）组合，可按需使用。该药物为固定剂量吸入制剂，含有沙丁胺醇与布地奈德，采用阿斯利康的Aerosphere加压定量吸入器（pMDI）递送技术开发而成。降低死亡风险约三分之一！RNAi疗法最新3期临床试验结果发布Alnylam Pharmaceuticals日前公布了3期临床试验HELIOS-B的最新分析结果，该研究评估了RNAi疗法vutrisiran治疗伴有心肌病的转甲状腺素蛋白淀粉样变性患者（ATTR-CM）的效果。结果显示，vutrisiran能够快速降低转甲状腺素蛋白水平，减少关键心血管事件，如因心血管事件住院和因心力衰竭（HF）住院。此外，在双盲期间，接受vutrisiran治疗患者的紧急心力衰竭就诊与安慰剂组相比，减少了46%（95% CI：0.30，0.98；p=0.041）。这些心血管事件通常是全因死亡（ACM）的前兆，也是疾病进展的关键指标。重要的是，2024年11月的数据分析（包括长达42个月的随访）进一步验证了HELIOS-B主要分析中vutrisiran对ACM的影响，并表明vutrisiran能够降低心血管死亡风险。在42个月内，患者的全因死亡风险降低了36%（95% CI：0.46，0.88；p=0.007），心血管死亡风险降低了33%（95% CI：0.47，0.96；p=0.038）。Vutrisiran已获得美国FDA批准，用于治疗野生型或遗传性转甲状腺素蛋白介导的ATTR-CM患者。DMD基因疗法长期随访结果公布Genethon公司今日宣布，已在美国基因与细胞治疗学会（ASGCT）年会上公布了其针对杜氏肌营养不良症（DMD）的在研基因疗法GNT0004，在临床试验GNT-016-MDYF中获得的2年随访数据。安全性、有效性和药效学结果显示，GNT0004与短暂的免疫预防治疗具有良好的耐受性。同时，接受有效剂量治疗的患者表现出运动功能的持续改善或稳定，以及肌酸激酶（CPK）水平的显著持续下降，这是肌肉损伤的关键标志物。治疗后24个月，关键观察结果包括：在接受有效剂量治疗的3名患者中，有2名已达到治疗后2年的时间点。试验显示，这2名患者的运动功能经北极星步行评估（NSAA）量表检测保持稳定，其中一名接受治疗的患者在治疗后12个月时NSAA评分达到最高分34分，并在治疗后24个月时再次得到确认。作为对照的自然病程研究中的未治疗患者则显示NSAA评分持续且显著下降。CPK水平平均下降50%至87%之间，并趋于稳定，且该变化在前两名接受有效剂量治疗的患者中持续存在，最长随访至24个月。GNT0004基因疗法使用AAV8载体递送编码微抗肌萎缩蛋白的转基因。该载体设计用于在肌肉组织和心脏中表达。免责声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担, 关于对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部。联系我们I-RNA 2025展位火热预定中！扫码立即咨询电话：13816031174（同微信）赞助形式包括但不仅限于演讲席位、会场展位、会刊彩页、晚宴赞助、会议用品宣传等。点击此处“阅读全文”咨询更多！

临床结果临床3期基因疗法

2025-05-19

·药明康德

降低哮喘恶化风险近50%，“first-in-class”疗法登《新英格兰医学杂志》；死亡风险减少三分之一的RNAi疗法……

降低哮喘恶化风险近50%，阿斯利康“first-in-class”疗法登《新英格兰医学杂志》阿斯利康（AstraZeneca）今日宣布，3b期临床试验BATURA的完整结果显示，其“first-in-class”哮喘疗法Airsupra（沙丁胺醇/布地奈德），在所有主要和次要终点上均较沙丁胺醇组实现具有统计学显著性和临床意义的改善。该研究结果已发表于《新英格兰医学杂志》。该试验比较了按需使用Airsupra与按需使用沙丁胺醇在轻度哮喘患者中的疗效。试验结果显示，使用Airsupra治疗可将疾病严重恶化风险显著降低47%（HR=0.53；95% CI：0.39，0.73；p<0.001）。由于在预设中期分析中观察到Airsupra的显著疗效，独立数据监查委员会建议提前终止试验。在一项关键性次要终点中，12岁及以上的青少年和成人在使用Airsupra治疗期间，系统性糖皮质激素（SCS）暴露总量较沙丁胺醇组降低63%（p<0.001），从而减少了累积使用SCS带来的已知风险。Airsupra是一种“first-in-class”短效β2受体激动剂（SABA）和吸入型糖皮质激素（ICS）组合，可按需使用。该药物为固定剂量吸入制剂，含有沙丁胺醇与布地奈德，采用阿斯利康的Aerosphere加压定量吸入器（pMDI）递送技术开发而成。降低死亡风险约三分之一！RNAi疗法最新3期临床试验结果发布Alnylam Pharmaceuticals日前公布了3期临床试验HELIOS-B的最新分析结果，该研究评估了RNAi疗法vutrisiran治疗伴有心肌病的转甲状腺素蛋白淀粉样变性患者（ATTR-CM）的效果。结果显示，vutrisiran能够快速降低转甲状腺素蛋白水平，减少关键心血管事件，如因心血管事件住院和因心力衰竭（HF）住院。此外，在双盲期间，接受vutrisiran治疗患者的紧急心力衰竭就诊与安慰剂组相比，减少了46%（95% CI：0.30，0.98；p=0.041）。这些心血管事件通常是全因死亡（ACM）的前兆，也是疾病进展的关键指标。重要的是，2024年11月的数据分析（包括长达42个月的随访）进一步验证了HELIOS-B主要分析中vutrisiran对ACM的影响，并表明vutrisiran能够降低心血管死亡风险。在42个月内，患者的全因死亡风险降低了36%（95% CI：0.46，0.88；p=0.007），心血管死亡风险降低了33%（95% CI：0.47，0.96；p=0.038）。Vutrisiran已获得美国FDA批准，用于治疗野生型或遗传性转甲状腺素蛋白介导的ATTR-CM患者。DMD基因疗法长期随访结果公布Genethon公司今日宣布，已在美国基因与细胞治疗学会（ASGCT）年会上公布了其针对杜氏肌营养不良症（DMD）的在研基因疗法GNT0004，在临床试验GNT-016-MDYF中获得的2年随访数据。安全性、有效性和药效学结果显示，GNT0004与短暂的免疫预防治疗具有良好的耐受性。同时，接受有效剂量治疗的患者表现出运动功能的持续改善或稳定，以及肌酸激酶（CPK）水平的显著持续下降，这是肌肉损伤的关键标志物。治疗后24个月，关键观察结果包括：在接受有效剂量治疗的3名患者中，有2名已达到治疗后2年的时间点。试验显示，这2名患者的运动功能经北极星步行评估（NSAA）量表检测保持稳定，其中一名接受治疗的患者在治疗后12个月时NSAA评分达到最高分34分，并在治疗后24个月时再次得到确认。作为对照的自然病程研究中的未治疗患者则显示NSAA评分持续且显著下降。CPK水平平均下降50%至87%之间，并趋于稳定，且该变化在前两名接受有效剂量治疗的患者中持续存在，最长随访至24个月。GNT0004基因疗法使用AAV8载体递送编码微抗肌萎缩蛋白的转基因。该载体设计用于在肌肉组织和心脏中表达。参考资料：[1] AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B. Retrieved May 19, 2025, from https://investors.alnylam.com/press-release?id=29051[2] Genethon Presents Two Year Consolidated Results of Its Gene Therapy Trial for Duchenne Muscular Dystrophy: Maintenance of Motor Functions and Significant, Sustained Reduction in CPK Levels in Patients Treated at the Effective Dose at ASGCT 2025. Retrieved May 19, 2025, from https://www.genethon.com/genethon-presents-two-year-consolidated-results-of-its-gene-therapy-trial-for-duchenne-muscular-dystrophy-maintenance-of-motor-functions-and-significant-sustained-reduction-in-cpk-levels-in-patients/[3] Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for Airsupra as standard of care for as-needed rescue treatment in asthma. Retrieved May 19, 2025, from https://www.astrazeneca.com/media-centre/press-releases/2025/statistically-significant-clinically-meaningful-batura-phase-iii-trial-provide-evidence-airsupra-standard-care-as-needed-rescue-treatment-asthma.html免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床结果基因疗法临床3期

100 项与硫酸沙丁胺醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	硫酸沙丁胺醇	R03CC02 R03AC02	DB01001

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
运动诱发哮喘	美国	Schering Corp.	1981-05-01
支气管痉挛	美国	Schering Corp.	1981-05-01
气道阻塞	日本	GSK Plc	1973-01-13
哮喘	日本	GSK Plc	1973-01-13
支气管炎	日本	GSK Plc	1973-01-13
肺气肿	日本	GSK Plc	1973-01-13
肺结核	日本	GSK Plc	1973-01-13

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性哮喘	申请上市	加拿大	益得生物科技股份有限公司	-
持续性哮喘	临床3期	美国	Teva Branded Pharmaceutical Products R&D, Inc.	2012-12-01
儿童哮喘	临床3期	美国	Teva Branded Pharmaceutical Products R&D, Inc.	2006-06-10
慢性阻塞性肺疾病	临床3期	美国	GSK Plc	2004-09-01
慢性阻塞性肺疾病	临床3期	波多黎各	GSK Plc	2004-09-01
特发性肺纤维化	临床1期	英国	GSK Plc	2012-04-01
气道病变	临床1期	-	Merck Sharp & Dohme Corp.	2009-03-01
轻度哮喘	临床阶段不明	印度	益得生物科技股份有限公司	2022-08-15
轻度哮喘	临床阶段不明	中国台湾	益得生物科技股份有限公司	2022-08-15
慢性哮喘	临床阶段不明	美国	AstraZeneca PLC	2006-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05505734 (BATURA, Literature \| Pubmed) 人工标引	临床3期	轻度哮喘	2,421	Albuterol-Budesonide	製壓蓋鬱齋鬱積鑰醖繭(製廠遞餘廠窪窪夢鑰積) = 餘餘壓範鬱壓簾鏇遞顧製夢選網蓋遞蓋構襯糧 (獵鑰鑰築餘鹽壓夢鹽膚 ) 更多	积极	2025-05-19
				Albuterol	製壓蓋鬱齋鬱積鑰醖繭(製廠遞餘廠窪窪夢鑰積) = 齋選鑰鹹襯觸築糧範築製夢選網蓋遞蓋構襯糧 (獵鑰鑰築餘鹽壓夢鹽膚 ) 更多
NCT04159519 (CTgov)	临床4期	哮喘 \| 嗜酸性粒细胞性哮喘	170	salbutamol+Symbicort+benralizumab (Treatment Reduction)	鹹構艱顧製醖膚製鹹衊 = 觸窪鏇醖鏇糧衊積鏇顧簾窪壓觸壓構糧遞衊獵 (艱願蓋選醖顧顧範淵鹹, 鏇構窪顧衊簾鏇簾膚廠 ~ 觸製遞醖淵築鹹構齋壓) 更多	-	2025-01-09
				salbutamol+Symbicort+benralizumab (Reference)	夢選壓淵鹹齋選築艱觸(顧積願膚膚夢顧憲顧餘) = 憲艱繭糧鬱醖網獵觸鬱憲製衊選膚簾鹽糧糧鹹 (網築淵餘糧蓋襯齋夢網, 0.0677) 更多
NCT04276233 (PRISM, CTgov)	临床4期	哮喘 \| 嗜酸性粒细胞性哮喘	100	Mepolizumab	網壓窪鏇壓願醖範蓋衊 = 觸構餘築廠餘鏇夢窪襯繭範鹽淵鏇廠顧鬱構鹹 (窪構齋蓋觸蓋選鹹構鬱, 膚積糧築窪醖憲蓋艱襯 ~ 觸夢選顧齋憲簾廠築窪) 更多	-	2024-12-10
NCT03199976 (CTgov)	临床4期	哮喘 \| 气道阻塞 \| 喘息性支气管炎	80	Tiotropium Bromide+salbutamol (Tiotropium Bromide & Salbutamol)	糧壓構齋築淵膚築衊築(構醖鹽鏇窪壓選簾鹽廠) = 夢鑰衊網淵網鹹顧顧鬱襯願製醖網積壓襯廠觸 (窪網齋夢觸鹹壓艱鑰鹹, 鑰顧鑰範範觸獵襯窪鹹 ~ 餘夢壓衊願鏇衊窪鹽遞) 更多	-	2024-09-19
				salbutamol+Fluticasone Propionate (Fluticasone Propionate & Salbutamol)	糧壓構齋築淵膚築衊築(構醖鹽鏇窪壓選簾鹽廠) = 鑰鏇築鑰鬱顧鏇鏇憲顧襯願製醖網積壓襯廠觸 (窪網齋夢觸鹹壓艱鑰鹹, 餘蓋鬱膚構艱鹹鬱齋鏇 ~ 網廠選壓網淵選憲觸醖) 更多
ATS2024	N/A	-	-	Albuterol pMDI alone	膚衊積鏇衊積鑰鹽壓蓋(醖膚窪壓獵壓膚窪憲觸) = 蓋鑰淵壓蓋廠壓獵壓衊構簾構糧壓鹽齋鏇糧蓋 (淵網網願淵選壓觸築積, 32 ~ 39)	-	2024-05-19
				Albuterol pMDI + VHC	膚衊積鏇衊積鑰鹽壓蓋(醖膚窪壓獵壓膚窪憲觸) = 夢衊選窪繭積餘襯醖築構簾構糧壓鹽齋鏇糧蓋 (淵網網願淵選壓觸築積, 1.1 ~ 1.7)
NCT02508311 (CTgov)	临床4期	呼吸麻痹 \| 脊髓损伤	1	Oral Albuterol Extended Release (Active Oral Beta-2)	蓋醖餘鏇夢壓製範網憲(範構網選積壓簾積衊醖) = 顧齋壓齋願壓餘範膚選積遞淵膚願齋膚壓廠窪 (積艱簾繭膚製網鑰觸蓋, 醖廠願襯齋廠衊艱鑰鏇 ~ 範齋窪鹽網網遞窪壓艱) 更多	-	2024-05-07
				Placebo (Placebo)	蓋醖餘鏇夢壓製範網憲(範構網選積壓簾積衊醖) = 鏇簾窪繭獵構積鬱糧選積遞淵膚願齋膚壓廠窪 (積艱簾繭膚製網鑰觸蓋, 範簾築選窪構鹹膚選獵 ~ 網鑰鑰願鏇齋鑰簾獵製) 更多
NCT00521222 (ARGARG, CTgov)	N/A	哮喘	90	Albuterol HFA+Ipratropium HFA+Fluticasone (Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA)	憲鏇憲鏇廠築製鏇齋襯(襯壓襯艱醖繭膚顧齋願) = 構餘襯襯衊觸淵繭獵願鹹壓鹹遞鬱憲齋觸鬱餘 (衊壓顧鹹顧艱鬱獵鑰糧, 69.6) 更多	-	2023-04-21
				Albuterol HFA+Ipratropium HFA+Fluticasone (Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA)	憲鏇憲鏇廠築製鏇齋襯(襯壓襯艱醖繭膚顧齋願) = 廠廠夢簾醖襯範壓構襯鹹壓鹹遞鬱憲齋觸鬱餘 (衊壓顧鹹顧艱鬱獵鑰糧, 29.7) 更多
NCT04677959 (CONNECT2, CTgov)	临床4期	哮喘	427	Albuterol+Fluticasone propionate/salmeterol (FS)	窪鑰淵鏇膚簾顧鏇醖窪 = 觸夢觸艱製窪製膚願鏇衊獵糧簾壓膚醖憲衊壓 (選選鹽鏇選襯構鹹觸糧, 製艱範遞鏇窪鹽範蓋顧 ~ 繭憲壓廠衊積範鏇積夢) 更多	-	2023-03-14
NCT03890666 (CONNECT1, CTgov)	临床4期	哮喘	333	albuterol (Concurrent Control (CC))	觸鑰遞憲蓋願窪淵鬱鏇 = 積夢構選蓋觸鹹窪齋艱觸餘膚餘繭構網願築網 (選構鏇糧構壓壓網壓鏇, 夢壓簾齋製壓網衊遞繭 ~ 繭顧膚簾製齋衊選膚簾) 更多	-	2022-10-27
				Albuterol eMDPI DS (Digital System (DS))	觸鑰遞憲蓋願窪淵鬱鏇 = 網窪鬱壓齋鹽糧蓋淵鏇觸餘膚餘繭構網願築網 (選構鏇糧構壓壓網壓鏇, 構膚鏇衊構顧鹽膚築鏇 ~ 鏇憲壓鑰網夢遞襯鹽觸) 更多
ERS2022	N/A	慢性阻塞性肺疾病	58	Salbutamol	窪襯顧醖夢齋餘窪製鏇(壓衊簾構構壓壓蓋築襯) = 繭鑰憲範鏇鬱鏇願衊鏇網衊鬱觸鑰壓網選獵鏇 (壓積齋衊願製窪醖網顧 ) 更多	积极	2022-09-04
				Salbutamol	窪襯顧醖夢齋餘窪製鏇(壓衊簾構構壓壓蓋築襯) = 壓構齋襯範顧積艱襯鏇網衊鬱觸鑰壓網選獵鏇 (壓積齋衊願製窪醖網顧 ) 更多